Colfosceril Palmitate | 129Y-83 | DPPC | CAS#63-89-8 | Lung Surfactant | Neonatal Resiratory Distress Syndrome Treatment

MedKoo Cat#: 329102 | Name: Colfosceril Palmitate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Colfosceril Palmitate, also known as 129Y-83 and DPPC, is the primary surface-active agent of natural lung surfactant and the major constituent of exogenous surface replacement preparations. Colfosceril Palmitate is used for the prophylaxis and treatment of neonatal respiratory distress syndrome.

Chemical Structure

Colfosceril Palmitate

CAS#63-89-8

Theoretical Analysis

MedKoo Cat#: 329102

Name: Colfosceril Palmitate

CAS#: 63-89-8

Chemical Formula: C40H80NO8P

Exact Mass: 0.0000

Molecular Weight: 734.05

Elemental Analysis: C, 65.45; H, 10.99; N, 1.91; O, 17.44; P, 4.22

Price and Availability

Size	Price	Availability	Quantity
200mg	USD 350.00	2 Weeks
1g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Colfosceril Palmitate; 129Y-83; DPPC; 129Y 83; 129Y83; PC(16:0/16:0); L-DPPC; 1,2-DPPC; L-Dipalmitoyl Lecithin; 16:0/16:0-PC

IUPAC/Chemical Name

(R)-2,3-bis(palmitoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate

InChi Key

KILNVBDSWZSGLL-KXQOOQHDSA-N

InChi Code

InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1

SMILES Code

CCCCCCCCCCCCCCCC(O[C@@H](COP([O-])(OCC[N+](C)(C)C)=O)COC(CCCCCCCCCCCCCCC)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 734.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Dechant KL, Faulds D. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome. Drugs. 1991 Nov;42(5):877-94. doi: 10.2165/00003495-199142050-00009. PMID: 1723378. 2: Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs. Drug Ther Bull. 1991 Jun 10;29(12):46. PMID: 1935584. 3: Backhouse ME, Mauskopf JA, Jones D, Wold DE, Schumacher R, Cotton R, Long WA. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: results from a randomised trial. Pharmacoeconomics. 1994 Oct;6(4):358-69. doi: 10.2165/00019053-199406040-00003. PMID: 10147473. 4: Bryson HM, Whittington R. Colfosceril palmitate. A pharmacoeconomic evaluation of a synthetic surfactant preparation (Exosurf Neonatal) in infants with respiratory distress syndrome. Pharmacoeconomics. 1994 Dec;6(6):563-77. doi: 10.2165/00019053-199406060-00009. PMID: 10155285. 5: Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R; International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005 Apr;115(4):1018-29. doi: 10.1542/peds.2004-2183. PMID: 15805380. 6: Onrust SV, Dooley M, Goa KL. Calfactant: a review of its use in neonatal respiratory distress syndrome. Paediatr Drugs. 1999 Jul-Sep;1(3):219-43. doi: 10.2165/00128072-199901030-00006. PMID: 10937453. 7: Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs. 1996 Feb;51(2):226-37. doi: 10.2165/00003495-199651020-00004. PMID: 8808165. 8: Ishisaka DY. Exogenous surfactant use in neonates. Ann Pharmacother. 1996 Apr;30(4):389-98. doi: 10.1177/106002809603000412. PMID: 8729894. 9: Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group. Online J Curr Clin Trials. 1992 Nov 10;Doc No 28:[3886 words; 47 paragraphs]. PMID: 1343614. 10: Abrahamson EL, Viswanath M, Kovar IZ, Jawad SA. Unilateral pulmonary interstitial emphysema and treatment with colfosceril palmitate. Lancet. 1993 Jun 19;341(8860):1603. doi: 10.1016/0140-6736(93)90745-3. PMID: 8099684. 11: DeAngelis RL, Findlay JW. Metabolism of synthetic surfactants. Clin Perinatol. 1993 Dec;20(4):697-710. PMID: 8131363. 12: Patel DV, Bansal SC, Shah M, Patel CL, Patil K, Nimbalkar SM. Natural Versus Synthetic Surfactant Therapy in Respiratory Distress Syndrome of Prematurity. Indian J Pediatr. 2022 Nov;89(11):1086-1092. doi: 10.1007/s12098-022-04166-4. Epub 2022 Jun 1. PMID: 35648309. 13: Moen MD, Perry CM, Wellington K. Lucinactant: in neonatal respiratory distress syndrome. Treat Respir Med. 2005;4(2):139-45; discussion 146-7. doi: 10.2165/00151829-200504020-00008. PMID: 15813666. 14: Chan CY, Barton TL, Rasch DK. Colfosceril in an infant with adult respiratory distress syndrome. Clin Pharm. 1992 Oct;11(10):880-2. PMID: 1341995. 15: Gu RX, Baoukina S, Tieleman DP. Cholesterol Flip-Flop in Heterogeneous Membranes. J Chem Theory Comput. 2019 Mar 12;15(3):2064-2070. doi: 10.1021/acs.jctc.8b00933. Epub 2019 Feb 4. PMID: 30633868. 16: Hu Y, Chen J, Xu Y, Zhou H, Huang P, Ma Y, Gao M, Cheng S, Zhou H, Lv Z. Alterations of Gut Microbiome and Metabolite Profiling in Mice Infected by Schistosoma japonicum. Front Immunol. 2020 Oct 8;11:569727. doi: 10.3389/fimmu.2020.569727. PMID: 33162984; PMCID: PMC7580221. 17: N'Guessan A, Fattal E, Chapron D, Gueutin C, Koffi A, Tsapis N. Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids. Eur J Pharm Sci. 2018 Feb 15;113:185-192. doi: 10.1016/j.ejps.2017.09.013. Epub 2017 Sep 7. PMID: 28890202. 18: Shigematsu T, Koshiyama K, Wada S. Stretch-Induced Interdigitation of a Phospholipid/Cholesterol Bilayer. J Phys Chem B. 2018 Mar 8;122(9):2556-2563. doi: 10.1021/acs.jpcb.7b10633. Epub 2018 Feb 26. PMID: 29419298. 19: Kurniawan J, Ventrici J, Kittleson G, Kuhl TL. Interaction Forces between Lipid Rafts. Langmuir. 2017 Jan 10;33(1):382-387. doi: 10.1021/acs.langmuir.6b03717. Epub 2016 Dec 21. PMID: 28001077. 20: Maruscak A, Lewis JF. Exogenous surfactant therapy for ARDS. Expert Opin Investig Drugs. 2006 Jan;15(1):47-58. doi: 10.1517/13543784.15.1.47. PMID: 16370933.